Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with ...
A recurrence risk of less than 0.5% at 6 years after surgery may provide a practical definition of “cure” in the setting of colon cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback